[Technology Appraisal Guidance] Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib

NICE | June 2019| Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib Technology appraisal guidance [TA586]

NICE has published Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.

This guidance looks at the use of lenalidomide for multiple myeloma as second-line treatment. For third- or further-line use, please see NICE’s technology guidance on lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies.

Full details from NICE 

One thought on “[Technology Appraisal Guidance] Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s